A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Inclusion Criteria

• Age ≥18 years.
• Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma.
• Eastern Cooperative Oncology Group performance status 0 or 1.
• Adequate renal, liver, cardiac and pulmonary organ function.
• Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion. Key

Exclusion Criteria

• Prior treatment with anti-CD70 targeting agents
• History of certain central nervous system (CNS), cardiac or pulmonary conditions.
• Presence of uncontrolled bacterial, viral, or fungal infection.
• Active HIV, hepatitis B virus or hepatitis C virus infection.
• Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
• Women who are pregnant or breastfeeding.